Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Pilot Study to Evaluate the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction. IDA53 Trial. A FILO Study.

NCT03734198 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT03734198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03734198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Pilot Study to Evaluate the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction. IDA53 Trial. A FILO Study.
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 19, 2018
Completion date
December 19, 2025
Enrollment
29 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory chronic lymphocytic leukemia